Charged Alpha Stock Encyclopedia

Sysco Corporation (SYY) Q4 FY2026 — Q4 FY2026 (13 weeks ended June 27, 2026): sales $22.124B, UP 4.7%, a beat vs ~$21.95B. Adjusted diluted EPS $1.53 vs a $1.51 bar - a 2-cent BEAT. GAAP EPS $1.15. GAAP operating income +10.6% to $983M, but ADJUSTED operating income +4.1% and pretax earnings only +0.4%. FY2027 guided to 6-7% sales growth and 9-11% adjusted EPS growth ON A 53-WEEK BASIS. The 8-K wa...

Viasat, Inc. (VSAT) Q1 FY2027 — Q1 FY2027 (three months ended June 30, 2026): revenue $1,156.5M, DOWN 1.2%, a miss vs ~$1,199.7M. Non-GAAP diluted EPS $0.17 vs a $0.09 bar - an 8-cent BEAT. GAAP EPS $(0.38). Adjusted EBITDA $381.1M, DOWN 6.7%. Backlog a RECORD $4,217.7M, +18.9%. Net leverage 3.2x from 3.6x. FY2027 capex guided $950M-$1.0B against $992.8M spent last year - FLAT. The 8-K was accepte...

Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 — Q2 2026 (three months ended June 30): net sales $2,177.0M, +4.8% reported / +4.0% ORGANIC constant currency, vs a $2,134.8M consensus. Adjusted diluted EPS $2.07 vs a $2.01 bar - but FLAT year over year. GAAP diluted EPS $1.03. Adjusted net earnings FELL 2.8% to $399.6M and adjusted operating profit FELL 3.2%. FY2026 guidance RAISED to $8.47-$8.59. The...

US Foods Holding Corp (USFD) Q2 2026 — Q2 FY2026 (13 weeks ended June 27): net sales $10,532M, +4.5% vs a $10,463M consensus. Adjusted diluted EPS $1.44 vs a $1.36 bar - an 8-cent BEAT. GAAP diluted EPS $1.24, +29.2%. Adjusted EBITDA a RECORD $604M, +10.2%, margin +29bps to 5.7%. Independent restaurant cases +5.1%, a fourth straight quarter of acceleration. FY2026 guidance REAFFIRMED. The 8-K was...

Amrize Ltd (AMRZ) Q2 2026 — Q2 2026 (ended June 30, in USD under US GAAP): revenue $3,494M, +8.6% (organic +6.7%) vs $3,366M consensus - a $128M BEAT. Adjusted diluted EPS $0.88 vs a $0.95 bar - a 7.8% MISS. GAAP diluted EPS $0.86, +14.7%. Adjusted EBITDA $986M, +5.8%, margin 28.2%, -80bps. FY26 revenue guidance RAISED to $12.5-12.7B; FY26 Adjusted EBITDA guidance CUT to $3.1-3.2B from $3.25-3.34B...

Royalty Pharma plc (RPRX) Q2 2026 — Q2 2026 (ended June 30): Portfolio Receipts $773M, +6%; Royalty Receipts $768M, +14%; milestones $5M vs $56M, -91%. Net cash from operations $728M, +100%. Adjusted EBITDA $736M, +16%. Portfolio Cash Flow $736M, +15%. GAAP diluted EPS $0.04 (net income to RPRX plc $18M vs $32M) after a $472M non-cash swing in the provision for changes in expected cash flows: $268...

MPLX LP (MPLX) Q2 2026 — Q2 2026 (ended June 30): adjusted EBITDA attributable to MPLX $1,775M, +5.0%; Crude Oil and Products Logistics $1,161M +2.0%, Natural Gas and NGL Services $614M +11.2%; DCF $1,450M +2.1% (H1 $2,858M, DOWN 1.7%); net income attributable $1,077M; EPS $1.06 vs a $1.06 bar, in line; operating revenue $3,082M vs a $3,142M bar. Distribution $1.0765/unit, +12.5%, coverage 1.3x. A...

Kimberly-Clark Corporation (KMB) Q2 2026 — Q2 2026 (ended June 30): net sales $4,189M +0.6% (bar $4,225M, a small miss); organic sales -0.1%; adjusted EPS attributable to Kimberly-Clark $2.12 vs a $2.01 bar - a 5.5% BEAT, up 10.4% YoY; adjusted gross margin 38.8%, +190bp; adjusted operating profit $757M +6.2%; GAAP diluted EPS $1.04. North America $2,698M -1.2%, IPC $1,491M +4.0%. The 8-K was acce...

Joby Aviation, Inc. (JOBY) Q2 2026 — Q2 2026 (ended June 30): revenue $38.639M vs a $30.2M bar - a 28% BEAT; GAAP EPS -$0.25 vs -$0.234 - a narrow miss; GAAP net loss $245.4M, but adjusted EBITDA loss $197.0M vs $131.6M a year ago. R&D $194.7M +42.7%; SG&A $76.6M +143%; loss from operations $260.9M. FY2026 revenue guide RAISED to $115-125M from $105-115M. Cash + short-term investments $2.2...

Akamai Technologies, Inc. (AKAM) Q2 2026 — Q2 2026 (ended June 30): revenue $1,099.7M +5.4% (bar $1,091M, a beat); non-GAAP EPS $1.59 vs a $1.57 bar - a beat, and DOWN 8% YoY; GAAP EPS $0.52, down 27%; non-GAAP operating margin 25% vs 30%. Security $604M +10%, Cloud Infrastructure $99M +39%, Delivery $396M -6%. The 8-K was accepted 4:07pm ET Thursday Aug 6, so Friday Aug 7 is the reaction session:...

Maplebear Inc. (Instacart) (CART) Q2 2026 — Q2 2026 (ended June 30): GTV $10,351M +14%, revenue $1,043M +14% (bar $1,026M), adjusted EBITDA $313M +19% (bar $297.8M, a 5.1% BEAT), but GAAP diluted EPS $0.45 vs a $0.542 bar - a 16.6% MISS - and net income $111M, DOWN 4%. Orders 90.3M, up only 9%. The 8-K hit EDGAR at 4:09pm ET Thursday Aug 6, so Friday Aug 7 is the reaction session: $45.03 to $50.17...

Oklo Inc. (OKLO) Q2 2026 — Q2 2026 (ended June 30): revenue $1.21M - the first in company history - vs an estimate near $84K, but the 10-Q splits it into $800K of engineering and consulting, $168K of machining and $242K of other, all of it arriving with two engineering firms Oklo BOUGHT in June for $33.4M of cash. Cost of sales $721K, so gross profit was $489K. EPS -$0.28 vs a -$0.16 bar. Opex $74...

Devon Energy (DVN) Q2 2026 — Q2 2026 (ended June 30): total revenues $7,417M vs a $6,010M estimate - a $1,407M 'beat' that is $5,106M of wellhead oil, gas and NGL sales, $1,897M of zero-margin marketing pass-through and a $414M NON-CASH derivative mark. Wellhead sales alone were 15% BELOW the bar. Core EPS $1.57 vs $1.40 (+12.1%) is real; GAAP EPS $2.03. Oil 503 MBbl/d and 1,359 MBoe/d, both at th...

Charles River Laboratories (CRL) Q2 2026 — Q2 2026 (quarter ended June 27, 2026): revenue $1,004.1M vs $1,032.1M, DOWN 2.7% reported but UP 0.1% organic - the first organic growth since Q3 2023, ending nine straight down quarters. Non-GAAP diluted EPS $3.02 vs a $2.77 bar (+9.0%), but DOWN 3.2% from $3.12. GAAP diluted EPS $(0.03) vs $1.06, on a $63.7M loss from the CDMO and Cell Solutions divesti...

Keurig Dr Pepper (KDP) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): net sales $7,309M vs $4,163M, up 75.6% (constant currency +74.6%); excluding JDE Peet's, legacy KDP grew 7.3% on +4.2% price and +3.1% volume/mix. Adjusted diluted EPS $0.57 vs $0.49, +16.3%, against a Street bar near $0.537. But GAAP diluted EPS was $0.04, down 90.0%, and GAAP operating income FELL 30.1% to $628M while adjust...

Roivant Sciences (ROIV) Q1 FY2026 — Q1 FY2026 (quarter ended June 30, 2026): net loss per share $(0.26) vs $(0.33), a 21% improvement. Revenue was $1.4M - not billion, million; nothing in the portfolio is approved anywhere. Cash and securities $3.9B against $385M of total liabilities and zero debt. But the company's own adjusted net loss was $243.7M vs $170.1M (43% WORSE) and cash used in operatio...

Iron Mountain (IRM) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $2,029.1M vs $1,711.9M, +18.5% reported, +17.6% constant-currency and +16.8% organic. Storage rental $1,134.6M +12.3%; service $894.5M +27.4%. Net income $106.1M vs a $(43.3)M loss. Adjusted EPS $0.60 vs a $0.56 bar (+7.1% beat). Adjusted EBITDA $727.0M +15.7%, but margin fell 90bp to 35.8%. AFFO $432.7M +17.0%, $1.44/sha...

Becton Dickinson (BDX) Q3 FY2026 — Q3 FY2026 (quarter ended June 30, 2026): revenue $4,983M vs $4,726M, +5.4% reported and +4.4% currency-neutral, against a $4,887M bar - a 2.0% beat. GAAP diluted EPS from continuing operations $1.64 vs $1.57 (+4.5%); adjusted diluted EPS $3.23 vs $3.08 (+4.9%), against a $3.14 bar - a nine-cent BEAT. Total GAAP EPS including discontinued operations $1.37. FY2026...

Royal Gold (RGLD) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $450.5M vs $209.6M, up 114.9%, but 1.8% BELOW the $458.85M Street bar. GAAP EPS $2.78 vs $2.01; adjusted EPS $2.56 vs $1.81, against a $2.55 bar - a one-cent beat. GEOs sold 100,000 vs 63,900 (+56.5%). Record operating cash flow $335.2M. The 8-K was accepted at 5:14 p.m. ET Wednesday Aug 5, so Thursday Aug 6 was the reactio...

Zoetis (ZTS) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $2.468B vs $2.474B, flat reported and -1% organic operational, against a ~$2.50B Street bar (a 1.3% MISS). GAAP EPS $1.65 vs $1.63; adjusted EPS $1.87 vs $1.78, against a $1.85 bar. But adjusted NET INCOME fell 1%, from $791M to $781M - diluted shares went 445.5M to 417.7M. Companion Animal revenue -$82M; Livestock +$80M; total...

Republic Services (RSG) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $4.430B vs $4.235B, +4.6%, against a ~$4.41B Street bar. GAAP EPS $1.84 vs $1.75; adjusted EPS $1.85 vs $1.77, against a $1.81-$1.83 bar. Adjusted EBITDA $1.423B, margin 32.1%, flat YoY. Operating income $901M, +4.6%. But income before income taxes was $699M vs $720M, DOWN 2.9%, with the effective tax rate falling 23....

Halozyme Therapeutics (HALO) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): total revenue $481.0M vs $325.7M, +47.7%, against a ~$402M Street bar. Royalties $307.7M, +49.6%; product sales $129.6M, +59.0%. GAAP EPS $1.90 vs $1.33; non-GAAP net income $272.6M / $2.28 diluted EPS vs $191.3M / $1.54, against a $1.79 bar. Adjusted EBITDA $328.8M vs $225.5M, +45.8%, a 68.4% margin. Non-GAAP diluted sh...

Paycom (PAYC) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $531.2M vs $483.6M, +9.8%, against a ~$513.1M Street bar. Recurring and other revenue $505.2M, +11.0%, 95.1% of the total; interest on funds held for clients $26.0M vs $28.5M, DOWN 8.8%. GAAP net income $107.4M / $2.34 diluted EPS vs $89.5M / $1.58. Non-GAAP net income $127.7M / $2.78 diluted EPS vs $116.6M / $2.06, against a $...

Sempra (SRE) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): GAAP earnings $796M / $1.21 diluted EPS vs $461M / $0.71. Adjusted earnings $762M / $1.16 adjusted diluted EPS vs $583M / $0.89, against a Street bar of $1.07 - a $0.09 beat. Revenue $2,997M vs $3,000M, essentially flat, and 6.9% below the ~$3.22B consensus. Equity earnings $547M vs $393M. 2026 GAAP EPS guidance raised to $5.02-$5.55; 2...

Novo Nordisk A/S (NVO) Q2 2026 — Q2 2026 (quarter ended June 30, 2026), reported in Danish kroner: adjusted net sales DKK 78,488M, +7% at constant currency. Adjusted operating profit DKK 33,389M, +11% CER. Adjusted diluted EPS per ADR DKK 6.18 against a bar worth about DKK 5.01 - a 23% beat. IFRS diluted EPS was DKK 4.75, DOWN 20%; the gap is DKK 6,328M of non-cash pipeline impairments. FY2026 gui...